This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
UroGen Pharma, Ltd.
Drug Names(s): VesiGel
Description: VesiGel is a hydrogel-based sustained-release formulation of the chemotherapy, mitomycin C (MMC) using Urogen's Intra Cavity Drug Retention (ICDR) system.VesiGel formulates mitomycin C with the company's proprietary RTGel to create a sustained-release formulation. The company's gel formulation is liquid when chilled, but then solidifies in the body allowing a slow-release of the chemotherapy.
Additional information available to subscribers only: